SR 202 is a selective PPARγ antagonist which attenuates troglitazone-induced PPARγ transcriptional activity with IC50 value of 140μM. It inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo and improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.